Search

Your search keyword '"Emberton, M."' showing total 1,413 results
Start Over Author "Emberton, M."
1,413 results on '"Emberton, M."'

1. Focal HIFU and cryotherapy for prostate cancer: A HEAT and ICE analysis of 15-year usage trends in the United Kingdom

Author

Light, A., primary, Mayor, N., additional, Cullen, E., additional, Arya, M., additional, Grey, A., additional, Orczyk, C., additional, Moore, C.M., additional, Emberton, M., additional, Dudderidge, T., additional, Hindley, R., additional, Emara, A., additional, Noureldin, M., additional, Nigam, R., additional, Virdi, J., additional, Laniado, M., additional, Mccraken, S., additional, Greene, D., additional, Ahmed, H.U., additional, and Shah, T.T., additional

Published
2024
Full Text
View/download PDF

3. A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, H., primary, Wagner, T., additional, El-Sheikh, S., additional, Barod, R., additional, Patki, P., additional, Mumtaz, F., additional, Bex, A., additional, Campain, N., additional, Rogers, P., additional, O’Brien, T., additional, Hassan, F., additional, Stewart, G., additional, Mendichovszky, I., additional, Dizdarevic, S., additional, Alanbuki, A., additional, Wah, T., additional, Scarsbrook, A., additional, Wildgoose, W., additional, Vindrola-Padros, C., additional, Pizzo, E., additional, Dehbi, H.M., additional, Gurusamy, K., additional, Emberton, M., additional, and Tran, M.G.B., additional

Published
2023
Full Text
View/download PDF

4. NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy

Author

Neves, J.B, primary, Warren, H., additional, Santiapillai, J., additional, Rode, N., additional, Cullen, D., additional, Pavlou, M., additional, Walkden, M., additional, Patki, P., additional, Barod, R., additional, Mumtaz, F., additional, Aitchison, M., additional, Bandula, S., additional, Pizzo, E., additional, Ranieri, V., additional, Williams, N., additional, Wildgoose, W., additional, Gurusamy, K., additional, Emberton, M., additional, Bex, A., additional, and Tran, M.G.B., additional

Published
2023
Full Text
View/download PDF

7. Radical prostatectomy after vascular-targeted photodynamic therapy (VTP) with TOOKAD® : feasibility, early and intermediate results

Author

Pierrard, V., Lebdai, S., Kleinclauss, F., Azzouzi, A.-R., Terrier, J.E., Fortier, E., Joniau, S., Van Der Poel, H., Salomon, G., Casanova, J., Medina-Lopez, R.-A., Potiron, E., Rigaud, J., Vincendeau, S., Rassweiler, J., Villers, A., Gaston, R., Saussine, C., Giai, J., Gaillac, B., Emberton, M., and Ruffion, A.

Published
2018
Full Text
View/download PDF

8. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters

Author

Linch, M., Goh, G., Hiley, C., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y.N.S., King, H., Furness, A., Freeman, A., Linares, J., Akarca, A., Herrero, J., Rosenthal, R., Harder, N., Schmidt, G., Wilson, G.A., Birkbak, N.J., Mitter, R., Dentro, S., Cathcart, P., Arya, M., Johnston, E., Scott, R., Hung, M., Emberton, M., Attard, G., Szallasi, Z., Punwani, S., Quezada, S.A., Marafioti, T., Gerlinger, M., Ahmed, H.U., and Swanton, C.

Published
2017
Full Text
View/download PDF

9. ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses

Author

Ahmed, H.U., primary, Frangou, E., additional, Marsden, T., additional, Moore, C., additional, Shonit, P., additional, Singh, P., additional, Brew-Graves, C., additional, Clow, R., additional, Freeman, A., additional, Hadley, J., additional, Rawlins, F., additional, Santaolalla, A., additional, Rodriguez-Justo, M., additional, Syer, T., additional, Tuck, S., additional, Wingate, A., additional, Van Hemelrijk, M., additional, Attard, G., additional, Brown, L., additional, and Emberton, M., additional

Published
2023
Full Text
View/download PDF

18. The ReIMAGINE prostate cancer risk study protocol:A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses

Author

Marsden, T, McCartan, N, Brown, L, Rodriguez-Justo, M, Syer, T, Brembilla, G, Van Hemelrijck, M, Coolen, T, Attard, G, Punwani, S, Moore, CM, Ahmed, HU, Emberton, M, ReIMAGINE Study Group, and Medical Research Council (MRC)

Subjects
Image-Guided Biopsy, Male, Multidisciplinary, General Science & Technology, Prostate, Prostatic Neoplasms, Middle Aged, ReIMAGINE Study Group, Artificial Intelligence, Risk Factors, Biomarkers, Tumor, Humans, Multiparametric Magnetic Resonance Imaging, Neoplasm Grading, Ultrasonography, Interventional, Aged
Abstract

Introduction The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic). Methods ReIMAGINE Risk is an ethics approved (19/LO/1128) multicentre, prospective, observational cohort study which will recruit 1000 treatment-naive men undergoing a multi-parametric MRI (mpMRI) due to an elevated PSA (≤20ng/ml) or abnormal prostate examination who subsequently had a suspicious mpMRI (score≥3, stage ≤T3bN0M0). Primary outcomes include the detection of ≥Gleason 7 PCa at baseline and time to clinical progression, metastasis and death. Baseline blood, urine, and biopsy cores for fresh prostate tissue samples (2 targeted and 1 non-targeted) will be biobanked for future analysis. High-resolution scanning of pathology whole-slide imaging and MRI-DICOM images will be collected. Consortium partners will be granted access to data and biobanks to develop and validate biomarkers using correlation to mpMRI, biopsy-based disease status and long-term clinical outcomes. Results Recruitment began in September 2019(n = 533). A first site opened in September 2019 (n = 296), a second in November 2019 (n = 210) and a third in December 2020 (n = 27). Acceptance to the study has been 65% and a mean of 36.5ml(SD+/-10.0), 12.9ml(SD+/-3.7) and 2.8ml(SD+/-0.7) urine, plasma and serum donated for research, respectively. There are currently 4 academic and 15 commercial partners spanning imaging (~9 radiomics, artificial intelligence/machine learning), fluidic (~3 blood-based and ~2urine-based) and tissue-based (~1) biomarkers. Conclusion The consortium will develop, or adjust, risk models for PCa, and provide a platform for evaluating the role of novel diagnostics in the era of pre-biopsy MRI and targeted biopsy.

Published
2022

22. Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer

Author

Campistol Torres, M., primary, Morote, J., additional, Pye, H., additional, Athanasiou, A., additional, Celma, A., additional, Regis, L., additional, Planas, J., additional, Santamaria, A., additional, Trilla, E., additional, Schiess, R., additional, Punwani, S., additional, Whitaker, H., additional, Ahmed, H.U., additional, and Emberton, M., additional

Published
2022
Full Text
View/download PDF

30. P143 - NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy

Author

Neves, J.B, Warren, H., Santiapillai, J., Rode, N., Cullen, D., Pavlou, M., Walkden, M., Patki, P., Barod, R., Mumtaz, F., Aitchison, M., Bandula, S., Pizzo, E., Ranieri, V., Williams, N., Wildgoose, W., Gurusamy, K., Emberton, M., Bex, A., and Tran, M.G.B.

Published
2023
Full Text
View/download PDF

31. O04 - A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, H., Wagner, T., El-Sheikh, S., Barod, R., Patki, P., Mumtaz, F., Bex, A., Campain, N., Rogers, P., O’Brien, T., Hassan, F., Stewart, G., Mendichovszky, I., Dizdarevic, S., Alanbuki, A., Wah, T., Scarsbrook, A., Wildgoose, W., Vindrola-Padros, C., Pizzo, E., Dehbi, H.M., Gurusamy, K., Emberton, M., and Tran, M.G.B.

Published
2023
Full Text
View/download PDF

36. Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years

Author

Reddy, D.T., primary, Peters, M., additional, Shah, T., additional, Van Son, M., additional, Huber, P., additional, Lomas, D., additional, Rakauskas, A., additional, Miah, S., additional, Guillaumier, S., additional, Dudderidge, T., additional, Hindley, R., additional, Emara, A., additional, Nigam, R., additional, Valerio, M., additional, Afzal, N., additional, Lewi, H., additional, Orczyk, C., additional, Ogden, C., additional, Persad, R., additional, Virdi, J., additional, Moore, C., additional, Arya, M., additional, Winkler, M., additional, Emberton, M., additional, and Ahmed, H., additional

Published
2021
Full Text
View/download PDF

37. The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer

Author

Grey, A.D.R., primary, Scott, R., additional, Shah, B., additional, Acher, P., additional, Liyanage, S., additional, Pavlou, M., additional, Omar, R., additional, Chinegwundoh, F., additional, Patki, P., additional, Shah, T.T., additional, Hamid, S., additional, Ghei, M., additional, Brew-Graves, C., additional, Arumainayagam, N., additional, Chapman, A., additional, Mcleavy, L., additional, Alsaadi, Z., additional, Karatziotou, A., additional, Collins, T., additional, Eldred-Evans, D., additional, Freeman, A., additional, Winkler, M., additional, Emberton, M., additional, and Ahmed, H.U., additional

Published
2021
Full Text
View/download PDF

38. Focal ablative salvage therapy for radio-recurrent prostate cancer: 6 year oncological and safety outcomes

Author

Reddy, D.T., primary, Peters, M., additional, Shah, T., additional, Van Son, M., additional, Hosking-Jervis, F., additional, Miah, S., additional, Bertoncelli Tanaka, M., additional, Eldred-Evans, D., additional, Guillaumier, S., additional, Huber, P., additional, Lomas, D., additional, Rakauskas, A., additional, Dudderidge, T., additional, Mccracken, S., additional, Hindley, R., additional, Emara, A., additional, Nigam, R., additional, Persad, R., additional, Virdi, J., additional, Moore, C., additional, Orczyk, C., additional, Emberton, M., additional, Arya, M., additional, Winkler, M., additional, and Ahmed, H., additional

Published
2021
Full Text
View/download PDF

41. Retrospective evaluation of Proclarix as a companion to mpMRI for the detection of clinically significant prostate cancer

Author

Morote Robles, J., primary, Campistol Torres, M., additional, Celma, A., additional, Regis, L., additional, Planas, J., additional, Santamaria, A., additional, Trilla, E., additional, Schiess, R., additional, Pye, H., additional, Whitaker, H.C., additional, Steuber, T., additional, Ahmed, H.U., additional, and Emberton, M., additional

Published
2021
Full Text
View/download PDF

42. MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial

Author

Shah, T.T., primary, Kanthabalan, A., additional, Pavlou, M., additional, Adeleke, S., additional, Giganti, F., additional, Brew-Graves, C., additional, Williams, N.R, additional, Haroon, A., additional, Sidhu, H., additional, Freeman, A., additional, Orczyk, C., additional, Nikapota, A., additional, Dudderidge, T., additional, Hindley, R., additional, Virdi, J., additional, Arya, M., additional, Mitra, A., additional, Payne, H., additional, Bomanji, J., additional, Winkler, M., additional, Horan, G., additional, Moore, C., additional, Emberton, M., additional, Punwani, S., additional, and Ahmed, H.U, additional

Published
2021
Full Text
View/download PDF

45. PSA density and clinical outcome in MRI-based active surveillance for prostate cancer: A joint longitudinal-survival analysis

Author

Stavrinides, V., primary, Papageorgiou, G., additional, Danks, D., additional, Giganti, F., additional, Pashayan, N., additional, Trock, B., additional, Freeman, A., additional, Whitaker, H., additional, Allen, C., additional, Kirkham, A., additional, Sonn, G., additional, Punwani, S., additional, Barratt, D., additional, Emberton, M., additional, and Moore, C., additional

Published
2021
Full Text
View/download PDF

46. Role of MRI for the detection of prostate cancer

Author

Wu, R.C., Lebastchi, A.H., Hadaschik, B.A., Emberton, M., Moore, C., Laguna, P., Futterer, J.J., George, A.K., Wu, R.C., Lebastchi, A.H., Hadaschik, B.A., Emberton, M., Moore, C., Laguna, P., Futterer, J.J., and George, A.K.

Abstract

Item does not contain fulltext, The use of multiparametric MRI has been hastened under expanding, novel indications for its use in the diagnostic and management pathway of men with prostate cancer. This has helped drive a large body of the literature describing its evolving role over the last decade. Despite this, prostate cancer remains the only solid organ malignancy routinely diagnosed with random sampling. Herein, we summarize the components of multiparametric MRI and interpretation, and present a critical review of the current literature supporting is use in prostate cancer detection, risk stratification, and management.

Published
2021

47. Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?

Author

Ribeiro, L, Stonier, T, Stroman, L, Tourinho-Barbosa, R, Alghazo, O, Winkler, M, Dasgupta, P, Popert, R, Cathelineau, X, Sanchez-Salas, R, Murphy, DG, Emberton, M, Cathcart, P, Ribeiro, L, Stonier, T, Stroman, L, Tourinho-Barbosa, R, Alghazo, O, Winkler, M, Dasgupta, P, Popert, R, Cathelineau, X, Sanchez-Salas, R, Murphy, DG, Emberton, M, and Cathcart, P

Abstract

PURPOSE: To compare the toxicity profile and oncological outcome of salvage radical prostatectomy following focal therapy versus salvage radical prostatectomy after radiation therapies (external beam radiation therapy or brachytherapy). MATERIALS AND METHODS: Data concerning all men undergoing salvage radical prostatectomy for recurrent prostate cancer after either focal therapy, external beam radiation therapy or brachytherapy were retrospectively collected from 4 high volume surgical centers. The primary outcome measure of the study was toxicity of salvage radical prostatectomy characterized by any 30-day postoperative Clavien-Dindo complication rate, 12-month continence rate and 12-month potency rate. The secondary outcome was oncological outcome after salvage radical prostatectomy including positive margin rate and 12-month biochemical recurrence rate. Biochemical recurrence was estimated using Kaplan-Meier methods and significant differences were calculated using a log rank test. Median followup was 29.5 months. RESULTS: Between April 2007 and September 2018, 185 patients underwent salvage radical prostatectomy of whom 95 had salvage radical prostatectomy after focal therapy and 90 had salvage radical prostatectomy after radiation therapy (external beam radiation therapy or brachytherapy). Salvage radical prostatectomy after radiation therapy was associated with a significantly higher 30-day Clavien-Dindo I-IV complication rate (34% vs 5%, p <0.001). At 12 months following surgery, patients undergoing salvage radical prostatectomy after focal therapy had significantly better continence (83% pad-free vs 49%) while potency outcomes were similar (14% vs 11%). Men undergoing salvage radical prostatectomy after radiation therapy had a significantly higher stage and grade of disease together with a higher positive surgical margin rate (37% vs 13%, p=0.001). The 3-year biochemical recurrence after focal therapy was 35% compared to 32% after radiation therapy (p=0.76).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results